Sang Wook Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sang Wook Lee has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Geehyun Song
Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea
5 shared publications - Hongzoo Park
Department of Urology, Kangwon National University School of Medicine, Chuncheon, Korea
5 shared publications - Jeong Hyun Kim
Department of Urology, Kangwon National University School of Medicine, Chuncheon, Korea
5 shared publications - Jae Hung Jung
Department of Precision Medicine and Urology, Yonsei University Wonju College of Medicine, Wonju, Korea
4 shared publications - Hyun Chul Chung
Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea
3 shared publications - Beomgi So
Drpresso Inc, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67  (4) , 331-339
An artificial intelligence model integrating clinico-laboratory data and single nucleotide polymorphism-based genomic risk for prostate cancer diagnosis in Korean men
Jung JH, et al. Investig Clin Urol. 2026 ;67:e35. https://doi.org/10.4111/icu.20260002
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67  (4) , 331-339
Open AccessAn artificial intelligence model integrating clinico-laboratory data and single nucleotide polymorphism-based genomic risk for prostate cancer diagnosis in Korean men
Jung JH, et al. Investig Clin Urol. 2026 ;67:e35. https://doi.org/10.4111/icu.20260002
- Open Access
- 30 November 2024
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 22  (3) , 201-210
A Machine Learning Model for Prostate Cancer Prediction in Korean Men
Purpose: Unnecessary prostate biopsies for detecting prostate cancer (PCa) should be minimized. Therefore, this study developed a machine learning (ML) model to predict PCa in Korean men and evaluated its usability.Materials and Methods: We retrospectively analyzed clinical data from 928 patients who underwent prostate biopsies at Kangwon National University Hospital between May 2013 and May 2023. Of these, 377 (41.6%) were diagnosed with PCa, and 551 (59.4%) did not have cancer. For external validation, clinical data from 385 patients aged 48–89 years who underwent prostate biopsies from September 2005 to September 2023 at Wonju Severance Christian Hospital were also included. Twenty-two clinical features were used to develop an ML model to predict PCa. Features were selected based on their contributions to model performance, leading to the inclusion of 15 features. A meta-learner was constructed using logistic regression to predict the probability of PCa, and the classifier was trained and validated on randomly extracted training and test sets at an 8:2 ratio.Results: The prostate health index, prostate volume, age, nodule on digital rectal examination, and prostate-specific antigen were the top 5 features for predicting PCa. The area under the receiver operating characteristic curve (AUC) of the meta-learner logistic regression model was 0.89, and the accuracy, sensitivity, and specificity were 0.828, 0.711, and 0.909, respectively. Our model also showed excellent prediction performance for high-grade PCa, with a Gleason score of 7 or higher and an AUC of 0.903. Furthermore, we evaluated the performance of the model using external cohort clinical data and achieved an AUC of 0.863.Conclusions: Our ML model excelled in predicting PCa, specifically clinically significant PCa. Although extensive cross-validation in other clinical cohorts is needed, this ML model is a promising option for future diagnostics.
- 30 November 2024
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 22  (3) , 201-210
Open AccessA Machine Learning Model for Prostate Cancer Prediction in Korean Men
Purpose: Unnecessary prostate biopsies for detecting prostate cancer (PCa) should be minimized. Therefore, this study developed a machine learning (ML) model to predict PCa in Korean men and evaluated its usability.Materials and Methods: We retrospectively analyzed clinical data from 928 patients who underwent prostate biopsies at Kangwon National University Hospital between May 2013 and May 2023. Of these, 377 (41.6%) were diagnosed with PCa, and 551 (59.4%) did not have cancer. For external validation, clinical data from 385 patients aged 48–89 years who underwent prostate biopsies from September 2005 to September 2023 at Wonju Severance Christian Hospital were also included. Twenty-two clinical features were used to develop an ML model to predict PCa. Features were selected based on their contributions to model performance, leading to the inclusion of 15 features. A meta-learner was constructed using logistic regression to predict the probability of PCa, and the classifier was trained and validated on randomly extracted training and test sets at an 8:2 ratio.Results: The prostate health index, prostate volume, age, nodule on digital rectal examination, and prostate-specific antigen were the top 5 features for predicting PCa. The area under the receiver operating characteristic curve (AUC) of the meta-learner logistic regression model was 0.89, and the accuracy, sensitivity, and specificity were 0.828, 0.711, and 0.909, respectively. Our model also showed excellent prediction performance for high-grade PCa, with a Gleason score of 7 or higher and an AUC of 0.903. Furthermore, we evaluated the performance of the model using external cohort clinical data and achieved an AUC of 0.863.Conclusions: Our ML model excelled in predicting PCa, specifically clinically significant PCa. Although extensive cross-validation in other clinical cohorts is needed, this ML model is a promising option for future diagnostics.
- Open Access
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42  (1) , 168-177
Nomogram Using Prostate Health Index for Predicting Prostate Cancer in the Gray Zone: Prospective, Multicenter Study
Chung JH, et al. World J Mens Health. 2024 Jan;42(1):168-177. https://doi.org/10.5534/wjmh.220223
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42  (1) , 168-177
Open AccessNomogram Using Prostate Health Index for Predicting Prostate Cancer in the Gray Zone: Prospective, Multicenter Study
Chung JH, et al. World J Mens Health. 2024 Jan;42(1):168-177. https://doi.org/10.5534/wjmh.220223
- Open Access
- 1 January 2020
- Published by The Korean Urological Association in Investigative and Clinical Urology
- Vol. 61  (1) , 42-50
Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study
To evaluate the clinical utility of percentage of serum prostate-specific antigen (proPSA) to free PSA (%p2PSA) and the prostate health index (PHI) for predicting aggressive pathological outcomes of radical prostatectomy (RP) in Korean males. This prospective observational multicenter study included 160 Korean males who consecutively underwent RP. The predictive utility of preoperative %p2PSA and PHI for predicting the following pathological outcomes of RP including pT3 disease, pathologic Gleason sum ≥7, and Gleason sum upgrading was investigated using multivariate and decision-curve analyses. The PHI and %p2PSA levels were significantly higher in patients with pT3 disease, pathologic Gleason sum ≥7, and Gleason sum upgrading. On univariate analysis, PHI was an accurate predictor of pT3 disease, pathologic Gleason sum ≥7, and Gleason sum upgrading. Multivariate and decision curve analyses revealed that inclusion of PHI to a base multivariate model including total PSA, percentage free PSA, PSA density, percentage of positive biopsy core, biopsy Gleason sum, and clinical stage factors significantly increased its predictive accuracy; %p2PSA showed a similar result. However, PHI was a more valuable predictor of pathological outcomes of RP. This study revealed PHI and %p2PSA as preoperative biomarkers of pathological outcomes in Korean males who underwent RP for prostate cancer.
- 1 January 2020
- Published by The Korean Urological Association in Investigative and Clinical Urology
- Vol. 61  (1) , 42-50
Open AccessPreoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study
To evaluate the clinical utility of percentage of serum prostate-specific antigen (proPSA) to free PSA (%p2PSA) and the prostate health index (PHI) for predicting aggressive pathological outcomes of radical prostatectomy (RP) in Korean males. This prospective observational multicenter study included 160 Korean males who consecutively underwent RP. The predictive utility of preoperative %p2PSA and PHI for predicting the following pathological outcomes of RP including pT3 disease, pathologic Gleason sum ≥7, and Gleason sum upgrading was investigated using multivariate and decision-curve analyses. The PHI and %p2PSA levels were significantly higher in patients with pT3 disease, pathologic Gleason sum ≥7, and Gleason sum upgrading. On univariate analysis, PHI was an accurate predictor of pT3 disease, pathologic Gleason sum ≥7, and Gleason sum upgrading. Multivariate and decision curve analyses revealed that inclusion of PHI to a base multivariate model including total PSA, percentage free PSA, PSA density, percentage of positive biopsy core, biopsy Gleason sum, and clinical stage factors significantly increased its predictive accuracy; %p2PSA showed a similar result. However, PHI was a more valuable predictor of pathological outcomes of RP. This study revealed PHI and %p2PSA as preoperative biomarkers of pathological outcomes in Korean males who underwent RP for prostate cancer.
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33  (11) , e94
Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study
Park H, et al. J Korean Med Sci. 2018 Jan;33(11):e94. https://doi.org/10.3346/jkms.2018.33.e94
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33  (11) , e94
Open AccessDiagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study
Park H, et al. J Korean Med Sci. 2018 Jan;33(11):e94. https://doi.org/10.3346/jkms.2018.33.e94
- Open Access
- 21 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , 1-16
Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome
Interstitial cystitis/bladder pain syndrome (IC/BPS) is an intractable disease characterized by severe pelvic pain and urinary frequency. Mesenchymal stem cell (MSC) therapy is a promising approach to treat incurable IC/BPS. Here, we show greater therapeutic efficacy of human embryonic stem cell (hESC)-derived multipotent stem cells (M-MSCs) than adult bone-marrow (BM)-derived counterparts for treating IC/BPS and also monitor long-term safety and in vivo properties of transplanted M-MSCs in living animals. Controlled hESC differentiation and isolation procedures resulted in pure M-MSCs displaying typical MSC behavior. In a hydrochloric-acid instillation-induced IC/BPS animal model, a single local injection of M-MSCs ameliorated bladder symptoms of IC/BPS with superior efficacy compared to BM-derived MSCs in ameliorating bladder voiding function and histological injuries including urothelium denudation, mast-cell infiltration, tissue fibrosis, apoptosis, and visceral hypersensitivity. Little adverse outcomes such as abnormal growth, tumorigenesis, or immune-mediated transplant rejection were observed over 12-months post-injection. Intravital confocal fluorescence imaging tracked the persistence of the transplanted cells over 6-months in living animals. The infused M-MSCs differentiated into multiple cell types and gradually integrated into vascular-like structures. The present study provides the first evidence for improved therapeutic efficacy, long-term safety, and in vivo distribution and cellular properties of hESC derivatives in preclinical models of IC/BPS.
- 21 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , 1-16
Open AccessImproved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome
Interstitial cystitis/bladder pain syndrome (IC/BPS) is an intractable disease characterized by severe pelvic pain and urinary frequency. Mesenchymal stem cell (MSC) therapy is a promising approach to treat incurable IC/BPS. Here, we show greater therapeutic efficacy of human embryonic stem cell (hESC)-derived multipotent stem cells (M-MSCs) than adult bone-marrow (BM)-derived counterparts for treating IC/BPS and also monitor long-term safety and in vivo properties of transplanted M-MSCs in living animals. Controlled hESC differentiation and isolation procedures resulted in pure M-MSCs displaying typical MSC behavior. In a hydrochloric-acid instillation-induced IC/BPS animal model, a single local injection of M-MSCs ameliorated bladder symptoms of IC/BPS with superior efficacy compared to BM-derived MSCs in ameliorating bladder voiding function and histological injuries including urothelium denudation, mast-cell infiltration, tissue fibrosis, apoptosis, and visceral hypersensitivity. Little adverse outcomes such as abnormal growth, tumorigenesis, or immune-mediated transplant rejection were observed over 12-months post-injection. Intravital confocal fluorescence imaging tracked the persistence of the transplanted cells over 6-months in living animals. The infused M-MSCs differentiated into multiple cell types and gradually integrated into vascular-like structures. The present study provides the first evidence for improved therapeutic efficacy, long-term safety, and in vivo distribution and cellular properties of hESC derivatives in preclinical models of IC/BPS.
- Open Access
- 23 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , 4154
Effects of naftopidil on double-J stent-related discomfort: a multicenter, randomized, double-blinded, placebo-controlled study
To evaluate the effect of naftopidil 75 mg once daily for ureteral double-J (DJ) stent-related discomfort after a ureteroscopic procedure using a multicenter, randomized, double-blinded, placebo-controlled study. 100 patients with indwelled retrograde DJ ureteral stents after ureteroscopic stone removal or retrograde intrarenal surgery (RIRS) were randomized 1:1 to receive either placebo or naftopidil during the stenting period. At the time of stent removal, the Ureteral Stent Symptom Questionnaire (USSQ), the International Prostate Symptom Score and the total amount of used analgesics were reported. Of the 92 patients who completed the study, 49 patients were enrolled in the placebo group, and 43 patients in the naftopidil group. USSQ urinary symptom scores (30.90 vs. 29.23, p = 0.299) and USSQ body pain scores (22.28 vs. 19.58, respectively, p = 0.286) were lower in the naftopidil group than in the placebo group, but the difference was not significant. Multivariate analysis showed that the use of a ureteral access sheath during RIRS was the only significant predictor of postoperative DJ-related pain (OR = 2.736, p = 0.031). The use of naftopidil once daily did not significantly reduce DJ ureteral stent-related discomfort. Larger-scaled prospective studies should be conducted to evaluate the effects of naftopidil on DJ stent-related symptoms and surgeries.
- 23 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , 4154
Open AccessEffects of naftopidil on double-J stent-related discomfort: a multicenter, randomized, double-blinded, placebo-controlled study
To evaluate the effect of naftopidil 75 mg once daily for ureteral double-J (DJ) stent-related discomfort after a ureteroscopic procedure using a multicenter, randomized, double-blinded, placebo-controlled study. 100 patients with indwelled retrograde DJ ureteral stents after ureteroscopic stone removal or retrograde intrarenal surgery (RIRS) were randomized 1:1 to receive either placebo or naftopidil during the stenting period. At the time of stent removal, the Ureteral Stent Symptom Questionnaire (USSQ), the International Prostate Symptom Score and the total amount of used analgesics were reported. Of the 92 patients who completed the study, 49 patients were enrolled in the placebo group, and 43 patients in the naftopidil group. USSQ urinary symptom scores (30.90 vs. 29.23, p = 0.299) and USSQ body pain scores (22.28 vs. 19.58, respectively, p = 0.286) were lower in the naftopidil group than in the placebo group, but the difference was not significant. Multivariate analysis showed that the use of a ureteral access sheath during RIRS was the only significant predictor of postoperative DJ-related pain (OR = 2.736, p = 0.031). The use of naftopidil once daily did not significantly reduce DJ ureteral stent-related discomfort. Larger-scaled prospective studies should be conducted to evaluate the effects of naftopidil on DJ stent-related symptoms and surgeries.
- Open Access
- 1 January 2017
- Published by Korean Association of Urogenital Tract Infection and Inflammation in Urogenital Tract Infection
- Vol. 12  (1) , 15-21
Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Male Bladder Pain Syndrome/Interstitial Cystitis: How Are They Related?
Lee SW. Urogenit Tract Infect. 2017 Apr;12(1):15-21. https://doi.org/10.14777/uti.2017.12.1.15
- 1 January 2017
- Published by Korean Association of Urogenital Tract Infection and Inflammation in Urogenital Tract Infection
- Vol. 12  (1) , 15-21
Open AccessChronic Prostatitis/Chronic Pelvic Pain Syndrome and Male Bladder Pain Syndrome/Interstitial Cystitis: How Are They Related?
Lee SW. Urogenit Tract Infect. 2017 Apr;12(1):15-21. https://doi.org/10.14777/uti.2017.12.1.15
- Open Access
- 1 January 2013
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 54  (11) , 801-804
Psoas Abscess Secondary to Renal Tuberculosis in a Middle-aged Woman
Lee SW. Korean J Urol. 2013 Nov;54(11):801-804. https://doi.org/10.4111/kju.2013.54.11.801
- 1 January 2013
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 54  (11) , 801-804
Open AccessPsoas Abscess Secondary to Renal Tuberculosis in a Middle-aged Woman
Lee SW. Korean J Urol. 2013 Nov;54(11):801-804. https://doi.org/10.4111/kju.2013.54.11.801
- Open Access
- 1 January 2010
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 51  (3) , 216-218
An Aspergilloma Mistaken for a Pelviureteral Stone on Nonenhanced CT: A Fungal Bezoar Causing Ureteral Obstruction
Lee SW. Korean J Urol. 2010 Mar;51(3):216-218. http://dx.doi.org/10.4111/kju.2010.51.3.216
- 1 January 2010
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 51  (3) , 216-218
Open AccessAn Aspergilloma Mistaken for a Pelviureteral Stone on Nonenhanced CT: A Fungal Bezoar Causing Ureteral Obstruction
Lee SW. Korean J Urol. 2010 Mar;51(3):216-218. http://dx.doi.org/10.4111/kju.2010.51.3.216